Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

immatics Appoints Peter Chambré as Chairman

Published: Monday, November 12, 2012
Last Updated: Monday, November 12, 2012
Bookmark and Share
Peter Chambré will replace Thomas Widmann.

immatics biotechnologies GmbH has announced the appointment of Peter Chambré as Chairman of the Board with immediate effect.

Peter Chambré has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry.

He will replace Thomas Widmann, who has been Chairman of the Company since 2004.

Peter Chambré was CEO of Cambridge Antibody Technology (CAT), from 2002 until its acquisition by AstraZeneca in 2006.

Before joining CAT, Peter Chambré was Chief Operating Officer of Celera Genomics Group and, previously, CEO of Bespak plc, a drug delivery company.

Following these major executive roles in the sector, Peter Chambré has held several Chairman and Non-executive Director positions.

From 2008-2010, he was Chairman of ApaTech, a specialist in orthobiologic bone graft technologies, which was acquired by Baxter Inc. in March 2010, and from 2006-2012, Non-executive Director of BTG plc.

Peter Chambré currently holds Chairman and Non-executive Board roles with a number of companies.

Paul Higham, CEO of immatics, said: “I am delighted to welcome Peter as our new Chairman. We are approaching a crucial period at immatics, and Peter’s experience and track record in successfully developing biopharmaceutical companies will be invaluable, as we seek to produce a step-change in the treatment of cancer and maximize returns to our investors.”

Peter Chambré said: “immatics’ vaccines, based on the Company’s highly rational approach to cancer vaccine discovery, have already demonstrated very promising results in clinical trials. With IMA901, immatics’ lead multi-peptide based vaccine now in phase 3 development for renal cancer, and a number of other projects in clinical development, this is an extremely exciting company. On behalf of immatics, I would like to express my thanks to Thomas Widmann for his very significant contribution to the development of the Company over the past 8 years. I very much look forward to working with the Board and management, as immatics aims to improve outcomes for cancer patients and create value for all its stakeholders.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Immatics and MD Anderson Announce Launch of Immatics US, Inc.
Launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies.
Wednesday, August 26, 2015
New EU-funded Consortium to Develop Fully Personalized Cancer Vaccines
Multinational clinical trial treating glioblastoma patients with fully personalized therapeutic vaccines planned to start in 2014.
Friday, July 05, 2013
immatics Announces Publication of IMA901 Cancer Vaccine Data in Nature Medicine
Paper highlights clinical and immunological activity of IMA901 in renal cell carcinoma (RCC).
Thursday, August 16, 2012
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
The Epigenetic Influences of Chronic Pain
Researchers at Drexel University College of Medicine are aiming to identify new molecular mechanisms involved in pain.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
Mothers Obesity Could be Passed on in mtDNA
Obesity can predispose offspring in multiple generations to metabolic problems.
New Imaging Method Reveals Nanoscale Details about DNA
Enhancement to super-resolution microscopy shows orientation of individual molecules, providing a new window into DNA’s structure and dynamics.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
Naked Mole Rat Exhibits “Extraordinary” Cancer Resistance
Scientists are getting closer to understanding the anti-cancer mechanism of the naked mole rat by making induced pluripotent stem cells.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!